Literature DB >> 28484921

Preoperative Prediction of Node-Negative Disease After Neoadjuvant Chemotherapy in Patients Presenting with Node-Negative or Node-Positive Breast Cancer.

Brittany L Murphy1,2, Tanya L Hoskin3, Courtney Day N Heins3, Elizabeth B Habermann1,2,3, Judy C Boughey4.   

Abstract

BACKGROUND: Axillary node status after neoadjuvant chemotherapy (NAC) influences the axillary surgical staging procedure as well as recommendations regarding reconstruction and radiation.
OBJECTIVE: Our aim was to construct a clinical preoperative prediction model to identify the likelihood of patients being node negative after NAC.
METHODS: Using the National Cancer Database (NCDB) from January 2010 to December 2012, we identified cT1-T4c, N0-N3 breast cancer patients treated with NAC. The effects of patient and tumor factors on pathologic node status were assessed by multivariable logistic regression separately for clinically node negative (cN0) and clinically node positive (cN+) disease, and two models were constructed. Model performance was validated in a cohort of NAC patients treated at our institution (January 2013-July 2016), and model discrimination was assessed by estimating the area under the curve (AUC).
RESULTS: Of 16,153 NCDB patients, 6659 (41%) were cN0 and 9494 (59%) were cN+. Factors associated with pathologic nodal status and included in the models were patient age, tumor grade, biologic subtype, histology, clinical tumor category, and, in cN+ patients only, clinical nodal category. The validation dataset included 194 cN0 and 180 cN+ patients. The cN0 model demonstrated good discrimination, with an AUC of 0.73 (95% confidence interval [CI] 0.72-0.74) in the NCDB and 0.77 (95% CI 0.68-0.85) in the external validation, while the cN+ patient model AUC was 0.71 (95% CI 0.70-0.72) in the NCDB and 0.74 (95% CI 0.67-0.82) in the external validation.
CONCLUSIONS: We constructed two models that showed good discrimination for predicting ypN0 status following NAC in cN0 and cN+ patients. These clinically useful models can guide surgical planning after NAC.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28484921     DOI: 10.1245/s10434-017-5872-9

Source DB:  PubMed          Journal:  Ann Surg Oncol        ISSN: 1068-9265            Impact factor:   5.344


  7 in total

1.  Predictive factors of an axillary pathological complete response of node-positive breast cancer to neoadjuvant chemotherapy.

Authors:  Naoko Iwamoto; Tomoyuki Aruga; Shinichiro Horiguchi; Chiaki Saita; Mai Onishi; Risa Goto; Toshiyuki Ishiba; Yayoi Honda; Hiromi Miyamoto; Katsumasa Kuroi
Journal:  Surg Today       Date:  2019-07-31       Impact factor: 2.549

2.  Tumor-infiltrating lymphocytes benefit prediction of axillary pathologic response and prognostication of event-free survival in HER2-positive and biopsy-proven node-positive breast cancer treated with neoadjuvant therapy.

Authors:  Shiwei Liu; Shiyan Zeng; Li Xia; Miao Yu; Xin Zhang; Hong Yang; Juan Ji; Hao Dong; Jianhui Zhang; Purong Zhang
Journal:  Breast Cancer Res Treat       Date:  2020-11-09       Impact factor: 4.872

3.  Does Tumor Size Predict Response to Neoadjuvant Chemotherapy in the Modern Era of Biologically Driven Treatment? A Nationwide Study of US Breast Cancer Patients.

Authors:  Devon Livingston-Rosanoff; Jessica Schumacher; Kara Vande Walle; Trista Stankowski-Drengler; Caprice C Greenberg; Heather Neuman; Lee G Wilke
Journal:  Clin Breast Cancer       Date:  2019-06-06       Impact factor: 3.225

4.  Sentinel Lymph Node Removal After Neoadjuvant Chemotherapy in Clinically Node-Negative Patients: When to Stop?

Authors:  Brittany L Murphy; James W Jakub; Malke Asaad; Courtney N Day; Tanya L Hoskin; Elizabeth B Habermann; Judy C Boughey
Journal:  Ann Surg Oncol       Date:  2020-08-20       Impact factor: 5.344

5.  Establishment and Verification of a Predictive Model for Node Pathological Complete Response After Neoadjuvant Chemotherapy for Initial Node Positive Early Breast Cancer.

Authors:  Jiujun Zhu; Dechuang Jiao; Min Yan; Xiuchun Chen; Chengzheng Wang; Zhenduo Lu; Lianfang Li; Xianfu Sun; Li Qin; Xuhui Guo; Chongjian Zhang; Jianghua Qiao; Jianbin Li; Zhimin Fan; Haibo Wang; Jianguo Zhang; Yongmei Yin; Peifen Fu; Cuizhi Geng; Feng Jin; Zefei Jiang; Shude Cui; Zhenzhen Liu
Journal:  Front Oncol       Date:  2021-04-29       Impact factor: 6.244

6.  Risk of Positive Sentinel Lymph Node After Neoadjuvant Systemic Therapy in Clinically Node-Negative Breast Cancer: Implications for Postmastectomy Radiation Therapy and Immediate Breast Reconstruction.

Authors:  S Samiei; B N van Kaathoven; L Boersma; R W Y Granzier; S Siesling; S M E Engelen; L de Munck; S M J van Kuijk; R R J W van der Hulst; M B I Lobbes; M L Smidt; T J A van Nijnatten
Journal:  Ann Surg Oncol       Date:  2019-07-29       Impact factor: 5.344

7.  Predicting pathological axillary lymph node status with ultrasound following neoadjuvant therapy for breast cancer.

Authors:  Signe Borgquist; Lisa Rydén; Ida Skarping; Daniel Förnvik; Sophia Zackrisson
Journal:  Breast Cancer Res Treat       Date:  2021-06-12       Impact factor: 4.872

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.